Park BJ, Taguchi H, Kamei K, Matsuzawa T, Hyon SH, Park JC. In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes.
Yonsei Med J 2011;
52:535-8. [PMID:
21488200 PMCID:
PMC3101062 DOI:
10.3349/ymj.2011.52.3.535]
[Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC₅₀, 2-4 μg/mL, MIC₉₀, 4-8 μg/mL, and geometric mean (GM) MICs, 3.36-4 μg/mL) than those of fluconazole (MIC₅₀, 2-16 μg/mL, MIC₉₀, 4-32 μg/mL, and GM MICs, 3.45-25.8 μg/mL) and flucytosin (MIC₅₀, MIC₉₀, and GM MICs, >64 μg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.
Collapse